Objective: To observe the efficacy of Aidi injection supplemental to chemotherapy in treatment of advanced esophageal carcinoma. Methods: Forty three cases of advanced esophageal carcinoma were randomly divided into two groups: 22 cases as the study group received Aidi injection combined with chemotherapy with the regimen of docetaxel and cisplantin, while 21 cases as the control group received the same chemotherapy. The efficacy, toxic reaction and compliance were observed in two groups. Results: The overall response rate of the study group was 59. 1% while the control group was 47. 6% ( P = 0. 03). The incidence of 3 ~ 4 grade toxicity of the study group was 27. 2% while the control group was 52.4% ( P = 0. 01) . The mean treatment courses of chemotherapy for the study group was 4. 7 while the control group was 3.4 (P = 0. 03 ) . The percentage of patients necessitated dose reduction and delay of chemotherapy in the study group were lower than those of the control group. Conclusion: Aidi injection can improve the response rate, decrease the toxicity and improve the tolerance of chemotherapy in advanced esophageal carcinoma.%目的:观察艾迪注射液配合化疗治疗晚期食管癌患者的疗效.方法:43例晚期食管癌患者随机分为2组:研究组22例,采用艾迪注射液配合多西他赛联合顺铂方案化疗；对照组21例,仅采用相同方案化疗.观察2组患者的有效率、毒性反应和顺应性.结果:研究组患者的总有效率高于对照组(59.1％ vs 47.6％,P=0.03).研究组3～4级毒性反应发生率低于对照组(27.2％vs 52.4％,P=0.01).研究组接受的平均化疗疗程数高于对照组(4.7 vs 3.4,P=0.03).研究组需要化疗减量和延迟的比例低于对照组.结论:艾迪注射液联合化疗治疗晚期食管癌患者,可提高缓解率、降低毒性反应并提高耐受性.
展开▼
